Literature DB >> 19026643

HSP90 is required for TAK1 stability but not for its activation in the pro-inflammatory signaling pathway.

Xin Yu Liu1, Cheah Chen Seh, Peter C F Cheung.   

Abstract

The protein kinase transforming-growth-factor-beta-activated kinase-1 (TAK1) is a key regulator in the pro-inflammatory signaling pathway and is activated by tumor necrosis factor-alpha, interleukin-1 (IL-1) and lipopolysaccharide (LPS). We describe the identification of TAK1 as a client protein of the 90 kDa heat-shock protein (Hsp90)/cell division cycle protein 37 (Cdc37) chaperones. However, Hsp90 is not required for the activation of TAK1 as short exposure to the Hsp90 inhibitor, 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) did not affect its activation by LPS or IL-1. Prolonged treatment of cells with 17-AAG inhibits Hsp90 and downregulates TAK1. Our results suggest that Hsp90 is required for the folding and stability of TAK1 but is displaced and no longer required when TAK1 is complexed to TAK1-binding protein-1 (TAB1).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19026643     DOI: 10.1016/j.febslet.2008.10.053

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

1.  Innate immunity kinase TAK1 phosphorylates Rab1 on a hotspot for posttranslational modifications by host and pathogen.

Authors:  Rebecca S Levin; Nicholas T Hertz; Alma L Burlingame; Kevan M Shokat; Shaeri Mukherjee
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

2.  Activation of the heat shock response attenuates the interleukin 1β-mediated inhibition of the amiloride-sensitive alveolar epithelial ion transport.

Authors:  Marybeth Howard; Jérémie Roux; Karen E Iles; Byron Miyazawa; Sarah Christiaans; Naseem Anjum; Dale A Dickinson; Arnaud Goolaerts; Michael A Matthay; Jean Francois Pittet
Journal:  Shock       Date:  2013-02       Impact factor: 3.454

3.  Regulation of cell proliferation and migration by TAK1 via transcriptional control of von Hippel-Lindau tumor suppressor.

Authors:  Siew Hwey Tan; Mintu Pal; Ming Jie Tan; Marc Hai Liang Wong; Fong U Tam; Jamie Wei Ting Teo; Han Chung Chong; Chek Kun Tan; Yan Yih Goh; Mark Boon Yang Tang; Peter Ching For Cheung; Nguan Soon Tan
Journal:  J Biol Chem       Date:  2009-05-06       Impact factor: 5.157

4.  Theissenolactone C Exhibited Ocular Protection of Endotoxin-Induced Uveitis by Attenuating Ocular Inflammatory Responses and Glial Activation.

Authors:  Fan-Li Lin; Jau-Der Ho; Yu-Wen Cheng; George C Y Chiou; Jing-Lun Yen; Hung-Ming Chang; Tzong-Huei Lee; George Hsiao
Journal:  Front Pharmacol       Date:  2018-04-09       Impact factor: 5.810

5.  Inducible HSP70 antagonizes IL-1β cytocidal effects through inhibiting NF-kB activation via destabilizing TAK1 in HeLa cells.

Authors:  Xiang Cao; Ling Yue; JiYun Song; Qiuyue Wu; Na Li; Lan Luo; Lei Lan; Zhimin Yin
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

Review 6.  The Potential of Hsp90 in Targeting Pathological Pathways in Cardiac Diseases.

Authors:  Richard J Roberts; Logan Hallee; Chi Keung Lam
Journal:  J Pers Med       Date:  2021-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.